Oral Semaglutide reduces heavy drinking in AUD trial
University of Colorado Anschutz researchers completed an eight‑week, randomized, double‑blind, placebo‑controlled trial of oral semaglutide in 50 adults with moderate‑to‑severe Alcohol Use Disorder. Participants took escalating doses (3 mg daily for four weeks, then 7 mg daily for four weeks). Compared with placebo, the semaglutide group recorded fewer heavy‑drinking days, lower alcohol consumption per drinking occasion, reduced day‑to‑day cravings, and fewer alcohol‑related problems, leading to an improved overall drinking‑risk level. The medication also reduced cannabis‑use days. No new FDA‑approved medication for Alcohol Use Disorder has been available since 2006, making the findings a notable clinical advance. The study was funded in part by the National Institute on Alcohol Abuse and Alcoholism and published in The American Journal of Psychiatry. Oral semaglutide was well tolerated with mostly mild side effects.
Entities
Alcohol Use Disorder · Alcohol Use Disorder (AUD) · American Journal of Psychiatry · Joseph Schacht · National Institute on Alcohol Abuse and Alcoholism · Oral semaglutide · Oral semaglutide · The American Journal of Psychiatry · University of Colorado Anschutz · University of Colorado Anschutz School of Medicine
Claims
What the coverage asserts, and how well corroborated each claim is across sources.
- [● 6 SOURCES] Participants receiving oral semaglutide showed an improved overall drinking risk level. news.cuanschutz.edu · celebrator.com · www.fanpage.it · gizmodo.com · www.forbes.com.au · +1 more
- [● 3 SOURCES] The semaglutide group reported lower day‑to‑day alcohol cravings. news.cuanschutz.edu · celebrator.com · www.fanpage.it
- [● 7 SOURCES] Oral semaglutide was tested in an eight‑week randomized, double‑blind, placebo‑controlled trial. news.cuanschutz.edu · celebrator.com · www.fanpage.it · gizmodo.com · razydzisiaj.pl · +2 more
- [● 7 SOURCES] Participants receiving oral semaglutide had fewer heavy drinking days than those on placebo. news.cuanschutz.edu · celebrator.com · www.fanpage.it · gizmodo.com · razydzisiaj.pl · +2 more
- [● 6 SOURCES] Oral semaglutide reduced cannabis‑use days among participants. news.cuanschutz.edu · celebrator.com · www.fanpage.it · gizmodo.com · www.forbes.com.au · +1 more
- [● 6 SOURCES] Oral semaglutide reduced alcohol consumption per drinking occasion. news.cuanschutz.edu · celebrator.com · www.fanpage.it · gizmodo.com · www.forbes.com.au · +1 more
- [● 3 SOURCES] The trial enrolled 50 adults with moderate‑to‑severe Alcohol Use Disorder. news.cuanschutz.edu · celebrator.com · www.fanpage.it
- [● 6 SOURCES] Participants on oral semaglutide experienced fewer alcohol‑related problems. news.cuanschutz.edu · celebrator.com · www.fanpage.it · gizmodo.com · www.forbes.com.au · +1 more
- [● 3 SOURCES] Oral semaglutide reduced heavy‑drinking days in adults with Alcohol Use Disorder. news.cuanschutz.edu · celebrator.com · www.fanpage.it
- [● 3 SOURCES] The study was conducted by the University of Colorado Anschutz School of Medicine and published in The American Journal of Psychiatry. news.cuanschutz.edu · celebrator.com · www.fanpage.it
- [● 6 SOURCES] Oral semaglutide reduced day‑to‑day alcohol cravings. news.cuanschutz.edu · celebrator.com · www.fanpage.it · gizmodo.com · www.forbes.com.au · +1 more
- [● 3 SOURCES] The trial was randomized, double‑blind, placebo‑controlled and involved 50 participants. news.cuanschutz.edu · celebrator.com · www.fanpage.it